Clinical Trial Update: A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing pyrotinib plus vinorelbine against physician's choice in HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN